Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2002

View Archived Issues

GSK researchers identify novel inhibitors of TGF-beta type I (ALK5) receptor

IDM and Epimmune enter license option agreement

Novel potassium channel openers under study at Abbott

New BACE-inhibitory peptide for AD and other Abeta-related disorders

Wyeth claims O-desmethylvenlafaxine salt and its use in depression, anxiety, etc.

New agents for thrombocytopenia described by Yamanouchi

Endothelin ETA antagonists described in BASF (Abbott) patent

Antibacterial compounds identified at Toagosei

New eNOS expression upregulators in early development at Aventis

AD-5423 and risperidone reported to be superior to haloperidol in schizophrenia

Potential use of a modified anti-CD3 therapy in psoriatic arthritis

Duloxetine in urinary stress incontinence

Unexpected efficacy reported for topiramate in psoriasis

Neurological benefits with motexafin gadolinium in cancer patients with brain metastases

Potential use of SU-5416 as a radiosensitizer in cancer therapy

rHuKGF reported to reduce morbidity from hyperfractionated radiotherapy plus chemotherapy

Anthrax vaccine advances to clinical testing at Walter Reed

Second pivotal trial of MT-300 demonstrates sustained relief of pain and symptoms

Cardiovascular drug collaboration initiated by BioFocus and Xention

Update on cancer trials for CP-461

Epothilones - a highly promising class of antitumor agents. An Integrity Case Study

Clinical potential for WHI-05 and WHI-07 as contraceptive microbicides

Beneficial effects of antimalarial agents in ITP and SLE

Clinical trials begin in Boehringer Ingelheim and ImmunoGen anticancer collaboration

LibiGel advances into phase II for FSD

Verteporfin + PDT assessed as multiple basal cell carcinoma treatment in phase III trials

Anadys and Sequoia collaborate to identify novel antiinfectives